EXTENDED REPORTS

Persistent clinical efficacy and safety of anti-tumour necrosis factor therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response

J Braun¹, X Baraliakos¹, J Listing², C Fritz², R Alten³, G Burmester⁴, A Krause⁵, S Schewe⁶, M Schneider⁷, H Sörensen⁸, H Zeidler⁹, J Sieper¹⁰

¹ Rheumatology Medical Center Ruhrgebiet, Herne
² German Rheumatism Research Center, Berlin
³ Schlosspark Clinic, Berlin
⁴ Charité Hospital, Humboldt University, Berlin
⁵ Berlin-Buch Hospital, Berlin
⁶ Ludwig-Maximilians-University, Munich
⁷ Heinrich-Heine-University, Düsseldorf
⁸ Immanuel Hospital, Berlin
⁹ Medical University, Hannover
¹⁰ University Medicine Berlin, Campus Benjamin Franklin, all Germany

Prof.Dr. J Braun, Rheumazentrum Ruhrgebiet, Landgrafenstr. 15, 44652 Herne, Germany; j.braun{at}rheumazentrum-ruhrgebiet.de

Background: There is insufficient evidence for the long-term efficacy and safety of anti-tumour necrosis factor therapy in patients with ankylosing spondylitis (AS). This is the first report on the treatment with infliximab over 5 years.

Methods: As part of a multicentre randomised trial, 69 patients with active AS at baseline (BL) have been continuously treated with infliximab (5 mg/kg i.v. every 6 weeks)—except for a short discontinuation after 3 years (FU1). The primary outcome of this extension was remission according to the ASsessment in Ankylosing Spondylitis (ASAS) criteria at the end of year 5 of the study (FU2).

Results: Of the 43 patients who completed year 3, 42 agreed to continue, 38 of which (90.5%) finished year 5 (55% of 69 initially). Partial clinical remission was achieved in 13 of 38 patients (34.2%) at FU1 and FU2. At FU2, the mean Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was 2.5±1.9 (BL:6.4, FU1:2.5). BASDAI values <4 were seen in 79% of patients at both, FU1 and FU2. ASAS 20% and 40% responses were seen in 32 (84%) and 24 (63%) patients at FU2, respectively. Most patients classified as non-responders at FU2 were part-time responders, as all but one patient achieved an ASAS 20% response at least once within the last 2 years. Three types of responders were identified. No major side effects occurred during years 4 and 5 of infliximab therapy.

Conclusions: Infliximab is safe and efficacious in AS patients over 5 years. The majority of the patients remained on treatment and had rather persistent levels of low disease activity. Different response types could be identified.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• BARALIAKOS, X., LISTING, J., von der RECKE, A., BRAUN, J. (2009). The Natural Course of Radiographic Progression in Ankylosing Spondylitis -- Evidence for Major Individual Variations in a Large Proportion of Patients. The Journal of Rheumatology 36: 997-1002 [Abstract] [Full Text]  
• Braun, J., Sieper, J. (2008). What is the most important outcome parameter in ankylosing spondylitis?. Rheumatology (Oxford) 47: 1738-1740 [Full Text]  
• Furst, D E, Keystone, E C, Kirkham, B, Fleischmann, R, Mease, P, Breedveld, F C, Smolen, J S, Kalden, J R, Burmester, G R, Braun, J, Emery, P, Winthrop, K, Bresnihan, B, De Benedetti, F, Dorner, T, Gibofsky, A, Schiff, M H, Sieper, J, Singer, N, Van Riel, P L C M, Weinblatt, M E, Weisman, M H (2008). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 67: iii2-iii25 [Full Text]